GSK (NYSE:GSK) Stock Unloaded Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently sold shares of GSK PLC Sponsored ADR (NYSE:GSK). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in GSK stock on October 31st. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

GSK Trading Down 0.3%

Shares of GSK stock opened at $47.03 on Tuesday. The company has a market capitalization of $95.49 billion, a P/E ratio of 13.29, a price-to-earnings-growth ratio of 1.90 and a beta of 0.50. The stock has a fifty day simple moving average of $44.37 and a 200 day simple moving average of $40.85. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $48.69. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.22. GSK had a return on equity of 51.07% and a net margin of 17.16%.The business had revenue of $11.35 billion for the quarter, compared to analysts’ expectations of $8.21 billion. During the same period last year, the business earned $0.50 EPS. The business’s revenue was up 6.7% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. On average, sell-side analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 8th. Investors of record on Friday, November 14th will be given a dividend of $0.4171 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $1.67 annualized dividend and a dividend yield of 3.5%. GSK’s payout ratio is presently 46.05%.

Analysts Set New Price Targets

GSK has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “buy (b)” rating on shares of GSK in a research report on Thursday. Jefferies Financial Group reissued a “buy” rating on shares of GSK in a research report on Monday, October 27th. Wall Street Zen upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. Finally, Cfra set a $53.00 price target on GSK in a research report on Thursday, October 30th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, GSK currently has an average rating of “Hold” and a consensus target price of $44.13.

Hedge Funds Weigh In On GSK

Several institutional investors and hedge funds have recently bought and sold shares of GSK. Dodge & Cox raised its stake in shares of GSK by 14.9% in the first quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company’s stock valued at $3,046,972,000 after buying an additional 10,210,921 shares during the period. Fisher Asset Management LLC increased its holdings in GSK by 2.8% in the 3rd quarter. Fisher Asset Management LLC now owns 32,227,615 shares of the pharmaceutical company’s stock worth $1,390,944,000 after acquiring an additional 889,210 shares during the last quarter. Primecap Management Co. CA increased its holdings in GSK by 1.8% in the 1st quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company’s stock worth $995,929,000 after acquiring an additional 446,360 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in GSK by 2.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company’s stock valued at $299,163,000 after acquiring an additional 155,392 shares during the period. Finally, Royal Bank of Canada lifted its holdings in GSK by 5.7% during the first quarter. Royal Bank of Canada now owns 7,581,079 shares of the pharmaceutical company’s stock valued at $293,692,000 after purchasing an additional 411,869 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.